Cyclic Gomesin [PYA1G, C2,6,11,15SeCys]

General Information


DRACP ID  DRACP00763

Peptide Name   Cyclic Gomesin [PYA1G, C2,6,11,15SeCys]

Sequence  GXRRLXYKQRXVTYXRGR

Sequence Length  18

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
CRL-1739 Human gastric adenocarcinoma cells Carcinoma CC50=51.0±4.6µM Resazurin assay 24h 1
MM96L Melanoma Carcinoma CC50=4.6±0.2µM Resazurin assay 24h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma CC50>64µM Resazurin assay 24h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma CC50=37.5±3.3µM Resazurin assay 24h 1
K562 Blast phase chronic myelogenous leukemia, BCR-ABL27 positive; Chronic myeloid leukemia Leukemia CC50=1.4±0.2µM Resazurin assay 24h 1
HL-60 Adult acute myeloid leukemia; Acute myeloid leukemia Leukemia CC50=38.5±4.8µM Resazurin assay 24h 1

Hemolytic Activity  Human erythrocytes: 32.8±0.5% Hemolysis=64µM

Normal (non-cancerous) Cytotoxicity  HFF-1: CC50=15.6±3.6µM; PBMC: CC50=15.5±0.8µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys2<--->Cys15; Cys6<--->Cys11; NCB: Gly1<--->Arg18

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  X=Se-Cys

Chiral  L



Physicochemical Information


Formula  C78H125N31O15

Absent amino acids  ACDEFHIMNPSW

Common amino acids  R

Mass  248043

Pl  12.34

Basic residues  6

Acidic residues  0

Hydrophobic residues  2

Net charge  6

Boman Index  -7770

Hydrophobicity  -144.44

Aliphatic Index  37.78

Half Life 
  /

Extinction Coefficient cystines  2980

Absorbance 280nm  175.29

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 28741926

Title  Redesigned Spider Peptide with Improved Antimicrobial and Anticancer Properties

Doi 10.1021/acschembio.7b00459

Year  2017

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.